Preclinical evaluation of a COVID-19 vaccine candidate based on a recombinant RBD fusion heterodimer of SARS-CoV-2

Current COVID-19 vaccines have been associated with a decline in infection rates, prevention of severe disease and a decrease in mortality rates. However, SARS-CoV-2 variants are continuously evolving, and development of new accessible COVID-19 vaccines is essential to mitigate the pandemic. Here, w...

Descripción completa

Detalles Bibliográficos
Autores: Barreiro Vázquez, Antonio|||0000-0001-6095-5077, Prenafeta, Antoni, Bech-Sàbat, Gregori, Roca, Mercè, Mur, Eva Perozo, March, Ricard, González-González, Luis, Madrenas, Laia, Corominas, Júlia, Fernández, Alex, Moros, Alexandra, Cañete, Manuel, Molas, Mercè, Pentinat-Pelegrin, Thais, Panosa, Clara, Moreno, Alberto, Molas, Ester Puigvert, Vilarrassa, Eva Pol, Palmada, Jordi, Garriga, Carme, Cabañas, Teresa Prat, Iglesias-Fernández, Javier, Vergara-Alert, Júlia|||0000-0001-7484-444X, Lorca-Oró, Cristina|||0000-0001-5351-4169, Roca, Núria, Fernández-Bastit, Leira|||0000-0002-7766-939X, Rodon, Jordi|||0000-0002-1032-9091, Pérez, Mònica, Segalés Coma, Joaquim|||0000-0002-1539-7261, Pradenas, Edwards|||0000-0001-5162-8920, Marfil, Sílvia|||0000-0003-0139-5000, Trinité, Benjamin|||0000-0003-3809-042X, Ortiz, Raquel|||0000-0002-6919-2026, Clotet Sala, Bonaventura|||0000-0003-3232-4598, Blanco, Julià|||0000-0002-2225-0217, Pedroza, Jorge Díaz, Carrasco, Rosa Ampudia, Salgado, Yaiza Rosales, Loubat-Casanovas, Jordina, Larripa, Sara Capdevila, Prado, Julia Garcia, Barretina, Jordi|||0000-0002-3478-4080, Sisteré-Oró, Marta|||0000-0003-0214-6348, Rica, Paula Cebollada, Meyerhans, Andreas|||0000-0003-0620-5317, Ferrer, Laura
Tipo de recurso: artículo
Fecha de publicación:2023
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:272497
Acceso en línea:https://ddd.uab.cat/record/272497
https://dx.doi.org/urn:doi:10.1016/j.isci.2023.106126
Access Level:acceso abierto
Palabra clave:SARS-CoV-2
COVID-19
Second-generation vaccines
RBD fusion heterodimer
Preclinical
Mice
Descripción
Sumario:Current COVID-19 vaccines have been associated with a decline in infection rates, prevention of severe disease and a decrease in mortality rates. However, SARS-CoV-2 variants are continuously evolving, and development of new accessible COVID-19 vaccines is essential to mitigate the pandemic. Here, we present data on preclinical studies in mice of a receptor-binding domain (RBD)-based recombinant protein vaccine (PHH-1V) consisting of an RBD fusion heterodimer comprising the B.1.351 and B.1.1.7 SARS-CoV-2 variants formulated in SQBA adjuvant, an oil-in-water emulsion. A prime-boost immunisation with PHH-1V in BALB/c and K18-hACE2 mice induced a CD4 + and CD8 + T cell response and RBD-binding antibodies with neutralising activity against several variants, and also showed a good tolerability profile. Significantly, RBD fusion heterodimer vaccination conferred 100% efficacy, preventing mortality in SARS-CoV-2 infected K18-hACE2 mice, but also reducing Beta, Delta and Omicron infection in lower respiratory airways. These findings demonstrate the feasibility of this recombinant vaccine strategy.

Similares en LA Referencia